TY - JOUR
T1 - Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity
AU - Naeimi Kararoudi, Meisam
AU - Tullius, Brian P.
AU - Chakraravarti, Nitin
AU - Pomeroy, Emily J.
AU - Moriarity, Branden S.
AU - Beland, Kathie
AU - Colamartino, Aurelien B.L.
AU - Haddad, Elie
AU - Chu, Yaya
AU - Cairo, Mitchell S.
AU - Lee, Dean A.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - Cancer immunotherapy using genetically modified immune cells such as those expressing chimeric antigen receptors has shown dramatic outcomes in patients with refractory and relapsed malignancies. Natural killer (NK) cells as a member of the innate immune system, possessing both anticancer (cytotoxic) and proinflammatory (cytokine) responses to cancers and rare off-target toxicities have great potential for a wide range of cancer therapeutic settings. Therefore, improving NK cell antitumor activity through genetic modification is of high interest in the field of cancer immunotherapy. However, gene manipulation in primary NK cells has been challenging because of broad resistance to many genetic modification methods that work well in T cells. Here we review recent successful approaches for genetic and epigenetic modification of NK cells including epigenetic remodeling, transposons, mRNA-mediated gene delivery, lentiviruses, and CRISPR gene targeting.
AB - Cancer immunotherapy using genetically modified immune cells such as those expressing chimeric antigen receptors has shown dramatic outcomes in patients with refractory and relapsed malignancies. Natural killer (NK) cells as a member of the innate immune system, possessing both anticancer (cytotoxic) and proinflammatory (cytokine) responses to cancers and rare off-target toxicities have great potential for a wide range of cancer therapeutic settings. Therefore, improving NK cell antitumor activity through genetic modification is of high interest in the field of cancer immunotherapy. However, gene manipulation in primary NK cells has been challenging because of broad resistance to many genetic modification methods that work well in T cells. Here we review recent successful approaches for genetic and epigenetic modification of NK cells including epigenetic remodeling, transposons, mRNA-mediated gene delivery, lentiviruses, and CRISPR gene targeting.
KW - CRISPR
KW - Cancer immunotherapy
KW - Genetic modification
KW - Natural killer cells
KW - Transposons
KW - Viral vectors
UR - http://www.scopus.com/inward/record.url?scp=85096589029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096589029&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2020.11.006
DO - 10.1053/j.seminhematol.2020.11.006
M3 - Article
C2 - 33256913
AN - SCOPUS:85096589029
SN - 0037-1963
VL - 57
SP - 201
EP - 212
JO - Seminars in hematology
JF - Seminars in hematology
IS - 4
ER -
